Evidence On Off-Label Bone Morphogenetic Protein Benefit Is Limited
This article was originally published in The Gray Sheet
Executive Summary
A draft technology assessment released April 23 by the Agency for Healthcare Research and Quality finds no evidence of improved health outcomes for most off-label uses of bone morphogenetic protein to promote bone healing following a fracture